TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05778188: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing

Sponsor: ReAlta Life Sciences, Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 70 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$1,826,000

Rescue Site Savings

+$1,195,200

Unlock Full NCT05778188 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05778188 Rescue Dossier →